TSRX Share Price

Open 13.68 Change Price %
High 13.76 1 Day -0.05 -0.37
Low 13.63 1 Week 0.00 0.00
Close 13.63 1 Month 0.00 0.00
Volume 5890879 1 Year 0.00 0.00
52 Week High 148.74
52 Week Low 29.51
TSRX Important Levels
Resistance 2 13.75
Resistance 1 13.70
Pivot 13.67
Support 1 13.56
Support 2 13.51
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Trius Therapeutics, Inc. (NASDAQ: TSRX)

TSRX Technical Analysis 5
As on 11th Sep 2013 TSRX Share Price closed @ 13.63 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.41 & Strong Buy for SHORT-TERM with Stoploss of 11.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TSRX Other Details
Segment EQ
Market Capital 209083728.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TSRX Address
TSRX
N/A
Interactive Technical Analysis Chart Trius Therapeutics, Inc. ( TSRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Trius Therapeutics, Inc.
TSRX Business Profile
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.